BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28231799)

  • 1. Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin.
    Agudo-López A; Prieto-García E; Alemán J; Pérez C; Díaz-García CV; Parrilla-Rubio L; Cabrera S; Navarro-Ranninger C; Cortés-Funes H; López-Martín JA; Agulló-Ortuño MT
    Mol Cancer; 2017 Feb; 16(1):45. PubMed ID: 28231799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation.
    Albino AP; Juan G; Traganos F; Reinhart L; Connolly J; Rose DP; Darzynkiewicz Z
    Cancer Res; 2000 Aug; 60(15):4139-45. PubMed ID: 10945621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of novel trans-sulfonamide platinum complexes against tumor cell lines.
    Pérez C; Díaz-García CV; Agudo-López A; del Solar V; Cabrera S; Agulló-Ortuño MT; Navarro-Ranninger C; Alemán J; López-Martín JA
    Eur J Med Chem; 2014 Apr; 76():360-8. PubMed ID: 24589491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors.
    Dong YB; Yang HL; Elliott MJ; McMasters KM
    Cancer Res; 2002 Mar; 62(6):1776-83. PubMed ID: 11912154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrovipecetin, a C-type lectin from Macrovipera lebetina venom, inhibits proliferation migration and invasion of SK-MEL-28 human melanoma cells and enhances their sensitivity to cisplatin.
    Hammouda MB; Riahi-Chebbi I; Souid S; Othman H; Aloui Z; Srairi-Abid N; Karoui H; Gasmi A; Magnenat EM; Wells TNC; Clemetson KJ; Rodríguez-López JN; Essafi-Benkhadir K
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):600-614. PubMed ID: 29196192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethylfumarate inhibits melanoma cell proliferation via p21 and p53 induction and bcl-2 and cyclin B1 downregulation.
    Kaluzki I; Hrgovic I; Hailemariam-Jahn T; Doll M; Kleemann J; Valesky EM; Kippenberger S; Kaufmann R; Zoeller N; Meissner M
    Tumour Biol; 2016 Oct; 37(10):13627-13635. PubMed ID: 27468725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
    Kato Y; Salumbides BC; Wang XF; Qian DZ; Williams S; Wei Y; Sanni TB; Atadja P; Pili R
    Mol Cancer Ther; 2007 Jan; 6(1):70-81. PubMed ID: 17237267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.
    Roubalová E; Kvardová V; Hrstka R; Borilová S; Michalová E; Dubská L; Müller P; Sova P; Vojtesek B
    Invest New Drugs; 2010 Aug; 28(4):445-53. PubMed ID: 19499188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
    Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
    PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Antiproliferative Activity of Oxypeucedanin via Induction of G
    Park SH; Hong JY; Park HJ; Lee SK
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
    Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
    Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
    Liu Y; Kwiatkowski DJ
    Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of miRNA-106b inhibits growth of melanoma cells by promoting G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1 protein.
    Prasad R; Katiyar SK
    Oncotarget; 2014 Nov; 5(21):10636-49. PubMed ID: 25361006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.
    Singh S; Davis R; Alamanda V; Pireddu R; Pernazza D; Sebti S; Lawrence N; Chellappan S
    Mol Cancer Ther; 2010 Dec; 9(12):3330-41. PubMed ID: 21139044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.
    Giudice S; Benassi L; Bertazzoni G; Veratti E; Morini D; Azzoni P; Costi MP; Venturelli A; Pirondi S; Seidenari S; Magnoni C
    Invest New Drugs; 2012 Aug; 30(4):1484-92. PubMed ID: 21881917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
    Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
    Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The p53-stabilizing compound, CP-31398, does not enhance chemosensitivity in human melanoma cells.
    Luu Y; Li G
    Anticancer Res; 2003; 23(1A):99-105. PubMed ID: 12680200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.